At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:29 ET
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,136,649 shares of Xenon Pharmaceuticals Inc. as of September 30, 2026, representing 11.5% of outstanding common stock. This is a routine quarterly update by a passive institutional investor; the stake level is consistent with prior filings.
- FMR LLC reported beneficial ownership of 11,136,649 shares of Xenon Pharmaceuticals common stock as of September 30, 2026.
- The stake represents 11.5% of outstanding shares.
- The filing is an amendment to Schedule 13G, indicating passive investment intent.
- Fidelity Management & Research Company LLC beneficially owns 5% or greater of the outstanding shares.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access